Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.
OS Therapies Incorporated (NYSE: OSTX) announced it had entered into an Asset Purchase Agreement with Ayala Pharmaceuticals, Inc. Under this agreement, OS Therapies will acquire all HER2 and Listeria ...
After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with ...
Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.
OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based ...
In a report released on January 29, Andrew Berens from Leerink Partners maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research ...
Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with ...
A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...